260 related articles for article (PubMed ID: 22307138)
1. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
2. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Meza-Junco J; Chu QS; Christensen O; Rajagopalan P; Das S; Stefanyschyn R; Sawyer MB
Cancer Chemother Pharmacol; 2009 Dec; 65(1):1-4. PubMed ID: 19672597
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Bins S; Lenting A; El Bouazzaoui S; van Doorn L; Oomen-de Hoop E; Eskens FA; van Schaik RH; Mathijssen RH
Pharmacogenomics; 2016 Sep; 17(14):1483-90. PubMed ID: 27533851
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms.
Mori S; Terada K; Ueki Y
Mod Rheumatol; 2012 Aug; 22(4):515-23. PubMed ID: 21993917
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
7. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
[TBL] [Abstract][Full Text] [Related]
8. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
[TBL] [Abstract][Full Text] [Related]
9. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
[TBL] [Abstract][Full Text] [Related]
10. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie PI; Uchaipichat V; Stek M; Lange JM; Phanuphak P; Cooper DA; Udomuksorn W; Miners JO
Pharmacogenet Genomics; 2006 May; 16(5):321-9. PubMed ID: 16609363
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
Gammal RS; Court MH; Haidar CE; Iwuchukwu OF; Gaur AH; Alvarellos M; Guillemette C; Lennox JL; Whirl-Carrillo M; Brummel SS; Ratain MJ; Klein TE; Schackman BR; Caudle KE; Haas DW;
Clin Pharmacol Ther; 2016 Apr; 99(4):363-9. PubMed ID: 26417955
[TBL] [Abstract][Full Text] [Related]
12. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
[TBL] [Abstract][Full Text] [Related]
13. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
[TBL] [Abstract][Full Text] [Related]
14. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
Culley CL; Kiang TK; Gilchrist SE; Ensom MH
Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
[TBL] [Abstract][Full Text] [Related]
15. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Iyer L; Hall D; Das S; Mortell MA; RamÃrez J; Kim S; Di Rienzo A; Ratain MJ
Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
17. UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia.
Carpenter SL; Lieff S; Howard TA; Eggleston B; Ware RE
Am J Hematol; 2008 Oct; 83(10):800-3. PubMed ID: 18756540
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
Panagopoulos P; Paraskevis D; Katsarolis I; Sypsa V; Detsika M; Protopapas K; Antoniadou A; Papadopoulos A; Petrikkos G; Hatzakis A
Int J STD AIDS; 2014 Oct; 25(12):860-5. PubMed ID: 24516079
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.
Singer JB; Shou Y; Giles F; Kantarjian HM; Hsu Y; Robeva AS; Rae P; Weitzman A; Meyer JM; Dugan M; Ottmann OG
Leukemia; 2007 Nov; 21(11):2311-5. PubMed ID: 17611564
[TBL] [Abstract][Full Text] [Related]
20. Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.
Collins KS; Metzger IF; Gufford BT; Lu JB; Medeiros EB; Pratt VM; Skaar TC; Desta Z
Drug Metab Dispos; 2020 Mar; 48(3):169-175. PubMed ID: 31888882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
